In short
Clinical trials are investigating ZINC, here studied as zinc acetate, to see how different dose regimens affect copper absorption. This Phase 2 study includes healthy participants and looks at a test related to Wilson disease. The main goal is to measure whether the treatment changes copper movement in the body.
Key points
- Clinical trials investigating ZINC are focused on Wilson's disease and copper absorption. The main study is a Phase 2 interventional trial in 36 healthy participants. It compares Galzin 50 mg, ET-700 75 mg, and placebo. The study uses 64Cu PET/CT imaging to measure how much copper tracer reaches the liver. The main endpoint is the change in mean hepatic 64Cu standard uptake value before and after treatment.
Trial overview
The clinical trial for ZINC is studying zinc acetate dose regimens in relation to Wilson's disease. It is an interventional study, which means researchers assign the treatments and then measure the effects.
This study is listed as Phase 2 and is authorised. The planned enrollment is 36 participants.
Study design and treatments
The study compares three treatment groups: Galzin 50 mg three times daily, ET-700 75 mg twice daily, and placebo. The trial summary says the goal is to see how these regimens affect intestinal copper absorption in healthy volunteers.
The trial also uses 64Cu PET/CT, a scan method that helps researchers track a copper tracer in the body. In this study, the amount of tracer found in the liver is used as a sign of copper absorption.
Who can participate
The available data say that the study is being done in healthy participants. No other inclusion or exclusion details are provided in the trial record.
This is important because the study is not testing people with Wilson's disease directly in the provided record. Instead, it is designed to help researchers understand copper absorption under controlled study conditions.
What is being measured
The main endpoint is the change in mean hepatic 64Cu standard uptake value (SUV) from before to after the intervention between the three groups. SUV is a number that shows how much of the tracer is taken up by an organ, here the liver.
Because the liver is a major organ for copper handling, this measurement helps researchers compare how the different regimens affect copper movement in the body. The study summary specifically says the scans are being used to assess intestinal copper absorption by measuring the amount of 64Cu in the liver.
What the results may mean for patients
For patients, this trial is mainly about learning whether different zinc acetate schedules change copper absorption in a measurable way. That information may help build better research knowledge for Wilson's disease.
The trial does not provide final results in the source data, so it cannot yet show which regimen works best. It does show that researchers are comparing active treatment with placebo and using imaging to measure the effect.
Key terms explained
Wilson's disease is the condition named in the trial record and is linked to copper handling in the body. Placebo means a look-alike treatment with no active study drug, used for comparison.
Interventional means the researchers give the treatments rather than only observing what happens. Authorised means the study has been approved to start according to the record provided.
Healthy volunteers are people without the disease being studied, and they help researchers make clearer comparisons. Endpoint means the main result the study is designed to measure.